Business Description
Nicox SA
ISIN : FR0013018124
Share Class Description:
XPAR:ALCOX: Share from reverse splitCompare
Compare
Traded in other countries / regions
ALCOX.FranceNXOA.Germany0RCQ.UKNICXF.USA IPO Date
1999-11-03Description
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.45 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 1.18 | |||||
| Debt-to-EBITDA | -1.56 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -14.59 | |||||
| Beneish M-Score | -6.31 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -77.3 | |||||
| 3-Year EBITDA Growth Rate | 8.2 | |||||
| 3-Year EPS without NRI Growth Rate | 8.3 | |||||
| 3-Year Book Growth Rate | -46.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 49.31 | |||||
| 9-Day RSI | 47.36 | |||||
| 14-Day RSI | 46 | |||||
| 6-1 Month Momentum % | -6.71 | |||||
| 12-1 Month Momentum % | -36.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.97 | |||||
| Quick Ratio | 8.97 | |||||
| Cash Ratio | 1.97 | |||||
| Days Sales Outstanding | 3767.41 | |||||
| Days Payable | 88.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.7 | |||||
| Shareholder Yield % | 2.41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -4475.88 | |||||
| Operating Margin % | -6810.51 | |||||
| Net Margin % | -8124.9 | |||||
| FCF Margin % | -8223.74 | |||||
| ROE % | -57.35 | |||||
| ROA % | -29.67 | |||||
| ROIC % | -34.7 | |||||
| ROC (Joel Greenblatt) % | -12767.1 | |||||
| ROCE % | -31.49 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 75.8 | |||||
| PB Ratio | 0.89 | |||||
| Price-to-Tangible-Book | 0.88 | |||||
| EV-to-EBIT | -1.66 | |||||
| EV-to-EBITDA | -2.04 | |||||
| EV-to-Forward-EBITDA | -1.24 | |||||
| EV-to-Revenue | 127.78 | |||||
| EV-to-Forward-Revenue | 3.91 | |||||
| EV-to-FCF | -1.54 | |||||
| Price-to-Median-PS-Value | 2.92 | |||||
| Price-to-Net-Current-Asset-Value | 0.97 | |||||
| Earnings Yield (Greenblatt) % | -60.24 | |||||
| FCF Yield % | -111.55 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers